Manufacturers report positive outcomes for durvalumab in first line treatment of extensive-stage small cell lung cancer, though addition of tremelimumab provides no benefit
Manufacturers state that data from the phase III CASPIAN trial detail that durvalumab, in combination with standard of care, confirmed a clinically meaningful and statistically significant improvement in overall survival.
Source:
Biospace Inc.
SPS commentary:
A separate arm investigated addition of tremelimumab (fully human monoclonal antibody against CTLA-4) to durvalumab and standard of care, but it was found to provide no benefit over durvalumab plus standard of care.